It also demonstrated clinical efficacy in combination with abiraterone in patients with metastatic prostate cancer with or without PTEN loss, in combination with paclitaxel in locally advanced or metastatic triple-negative breast cancer in LOTUS trial, and in combination with abiraterone in mCRPC with PTEN loss in IPATential150 [208,209,210]. The gene discussed is PTEN; the disease is triple-negative breast carcinoma.